Intêret du FibroScan® et des marqueurs biologiques de la fibrose hépatique, chez des sénégalais porteurs chroniques du virus de l’hépatite B faiblement réplicatifs

Touré, Papa Souleymane; Diop, M; Lô, Gora; Sow, A.I.; Veiga, Joana; Sarr, Mamadou Moustapha; Berthe, Adama; Dioussé, Pauline; Ndiaye, B.; Tall, Cheikh Tidiane; Diop, Bernard Marcel; Touré-Kane, Ndeye Coumba; Ka, Mamadou Mourtalla; Mboup, Souleymane

doi:10.1007/s12157-015-0634-4

Cited by 4 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…were similar to those of TOURE et al in Senegal, who found non-significant fibrosis in 82% and significant fibrosis in 18% [16]. The prevalence of significant fibrosis in our study could be justified by the fact that transaminases, viral load, and FibroScan were not evaluated on the same day in our patients.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Interest of non-Invasive Markers (APRI, FIB-4) for Assessing Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B without Cytolysis and with Low Viral Replication

Diakité,

Koffi,

Koné

et al. 2024

OJGas

View full text Add to dashboard Cite

Background and Objectives: The indication for treatment in HBsAg-positive patients with low viral load and normal transaminases requires an assessment of fibrosis. In resource-limited settings, free hepatic fibrosis evaluation tests can aid in therapeutic decision-making. Our study aims to demonstrate the utility of assessing hepatic fibrosis using non-invasive markers (APRI and FIB-4) in patients with chronic B viral hepatitis without cytolytic activity and low viral replication in our context. Patients and Methods: This is a retrospective cross-sectional study conducted between January 2018 and December 2021 at the University Hospital Center of Bouaké. Included were all patients aged ≥18 with normal transaminases (<40 IU/mL), low viral replication (<20,000 IU/mL), asymptomatic, and monoinfected with HBV. Patients with HIV or HCV coinfection or those who had received any antiviral treatment were excluded. FibroScan ® was performed on all patients. APRI and FIB-4 scores were calculated. The diagnostic performance of fibrosis markers was analyzed using the receiver operating curve (ROC) to compare them. Sensitivity, specificity, positive and negative predictive values, and the area under the curve (AUROC) were calculated for each marker with a 95% confidence interval. A p-value <0.05 was considered significant. Results: Our study included 241 patients, with a mean age of 36.19 years (±10.52 years) and a male predominance of 52%. The mean FibroScan ® value was 6.44 ± 2.3 kPa, and 68 patients (28.22%) had fibrosis >7 kPa. To exclude significant fibrosis (FS < 7 kPa), APRI and FIB-4 scores showed comparable performances, with sensitivity, specificity, positive predictive value, and negative predictive value of 90.

show abstract

Section: Discussionsupporting

confidence: 90%

“…In our series, the APRI and FIB-4 scores had comparable performance in ruling out significant fibrosis (LSM < 7. [16]. In our study, we reported an area under the ROC curve of 0.668 for the FIB-4 index and 0.752 for the APRI score in predicting significant fibrosis.…”

Section: Discussionmentioning

confidence: 49%

Interest of non-Invasive Markers (APRI, FIB-4) for Assessing Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B without Cytolysis and with Low Viral Replication

Diakité,

Koffi,

Koné

et al. 2024

OJGas

View full text Add to dashboard Cite

show abstract

“…In our population 45.88% had minimal or non-significant fibrosis, 54.12% had significant fibrosis. The results are variable in the literature depending on the cohorts Diallo I et al (Senegal 2016) found 57.14% of non-significant fibrosis and 42.86% of significant fibrosis [22] while Touré Ps et al (Senegal 2016) found 89.9% of non-significant fibrosis, 10.1% of significant fibrosis [10].…”

Section: Discussionmentioning

confidence: 97%

“…This invasive examination cannot therefore be repeated in the context of monitoring the evolution of liver fibrosis, hence the development of non-invasive alternatives with blood and morphological tests. Elastometry or fibroscan is a promising and reproducible non-invasive approach to the quantification of fibrosis [8] [9] [10].…”

Section: Introductionmentioning

confidence: 99%

Correlation between Ultrasound Aspects of Fibrosis and Fibroscan Outcomes of Patients with Chronic Hepatitis B Virus

Tiemtore-Kambou,

Koama,

Guingane

et al. 2023

OJRad

View full text Add to dashboard Cite

Background: The assessment of liver fibrosis is an essential part of the follow-up of patients with chronic HBV. Ultrasound and fibroscan are two commonly used non-invasive examinations and the purpose of this study is to assess the correlation between the results of these two examinations in the assessment of liver fibrosis. Methodology: This was a descriptive and analytical cross-sectional study with retrospective collection over a period of 30 months from January 01, 2018 to June 30, 2020 on the correlation between the ultrasound aspects and the results of the fibroscan of patients with chronic carriers of Hepatitis B virus at the Teaching Hospital of Bogodogo and at the faith-based health center CANDAF. Results: A total of 85 patients with fibrosis were collected. The 30 -40 age group was the most represented (41.18%), with a male predominance of 52.94%. The patients with a married life were the most represented (77.64%), the social stratum the most represented were the middle managers (32.94%). University level was predominant among education levels (45.64%). The personal history was traditional circumcision (34.12%), excision (21.18%), manicure (16.47%). The circumstances of the findings were blood donation (34.12%), screening (21.18%), fortuitous findings (16.47%). The association between echostructure and fibrosis on the fibroscan scan was significant (homogeneous hyperechoic echostructure p = 0.

show abstract

“…Ces résultats sont similaires au travail de To uré S. et al fait au Sénégal sur les porteursc hroniques du VHB faiblement réplicatifs[8]. La fibrose était non significativec hez la majorité de nos patient 89,1 %e tl afi brose est significatives eulement dans 10,1 %d ont le diagnostic de cirrhose dans 1% .P lusieurs études ont trouvé des résultats comparables notamment l'équipe du Sénégal[ 8], aussi dans le mémoire du Dr Charif Iliass fait au CHU de Fèse n2 013[9], seulement qu'il n'avait aucun cas de cirrhose dans sa série. Le même travail a été fait par l'équipe d'Alger avecN .G uessab et al où ils ont diagnostiqué la cirrhose dans 5,5 %[ 10].…”

unclassified

Évaluation initiale de la fibrose hépatique par le fibroscan chez les porteurs inactifs de l’AgHbs : à propos d’une étude monocentrique marocaine

Sokpon¹,

Amrani²,

Salihoun³

et al. 2016

Hegel

View full text Add to dashboard Cite

show abstract

Intêret du FibroScan® et des marqueurs biologiques de la fibrose hépatique, chez des sénégalais porteurs chroniques du virus de l’hépatite B faiblement réplicatifs

Cited by 4 publications

References 29 publications

Interest of non-Invasive Markers (APRI, FIB-4) for Assessing Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B without Cytolysis and with Low Viral Replication

Interest of non-Invasive Markers (APRI, FIB-4) for Assessing Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B without Cytolysis and with Low Viral Replication

Correlation between Ultrasound Aspects of Fibrosis and Fibroscan Outcomes of Patients with Chronic Hepatitis B Virus

Évaluation initiale de la fibrose hépatique par le fibroscan chez les porteurs inactifs de l’AgHbs : à propos d’une étude monocentrique marocaine

Contact Info

Product

Resources

About